AstraZeneca culls four early cancer drugs, including both prostate assets, in Q3 review

AstraZeneca removed four early-phase cancer programmes from its pipeline in its third-quarter update on 30 October 2026, including both of its early prostate cancer assets, while reporting 12 positive Phase III programme readouts so far this year¹².

What the update showed

The four culled assets were all in phase 1 or phase 1/2 testing². AZD9750, an oral androgen receptor degrader that entered the clinic in January, was dropped after pharmacokinetic and pharmacodynamic data². AstraZeneca had planned to treat 300 patients in its phase 1/2 study but stopped recruiting early in October after enrolling six². The molecule was designed to break down mutant and amplified forms of the receptor, a common route by which prostate tumours escape drugs such as Pfizer's Xtandi².

The second prostate programme, AZD8359, was a T-cell engager aimed at STEAP2 and weighted towards CD8-positive T cells to limit cytokine release². Its phase 1/2 trial started in May with a target of 42 patients, and AstraZeneca ended it, citing strategic reasons². In laboratory tests the molecule had cut cytokine release by 40% against a conventional T-cell engager².

The other two cuts were AZD2962, an IRAK4 inhibitor for blood cancers, and AZD8421, a selective CDK2 inhibitor². AstraZeneca closed the AZD8421 phase 1/2a study, which began in 2023, after recruiting 55 of a planned 564 patients².

The cuts sit against a larger late-stage book. AstraZeneca counts 180 projects in its pipeline, 116 new molecular entities or major life-cycle programmes in Phase II or Phase III, 20 NMEs in late-stage development and 2 under regulatory review¹. It has delivered 14 NMEs against a target of 20 by 2030¹. Since its Q4 2025 results it has won 47 approvals in major regions, including first approvals for four new medicines: Etcamah, Baxfendy, Klygefa and Amlypave¹. Tozorakimab, efzimfotase alfa and sonesitatug vedotin produced their first Phase III data¹.

Total revenue for the first nine months reached $46.9bn, up 7% at constant exchange rates, with Core EPS up 14% to $8.00¹. Oncology grew 16% to $21.9bn and now makes up 47% of revenue, while cardiovascular, renal and metabolism fell 14% as Farxiga and Brilinta lost exclusivity¹. The company reconfirmed its full-year guidance¹.

What it means for the market

For competitors and partners, the prostate exits thin out one large sponsor in two crowded early-stage approaches: oral receptor degraders built to overcome resistance to androgen receptor pathway inhibitors, and T-cell engagers against prostate surface antigens². AZD8359 had been designed specifically to address the cytokine release and off-tumour effects that limit dosing in that class, and AstraZeneca has not said whether that design fell short². IRAK4 remains a target that Pfizer and Gilead have also taken into the clinic².

The larger commercial story is late-stage. AstraZeneca puts the collective peak-year revenue potential of this year's positive Phase III readouts well above $10bn, and says its 2027 readouts could be worth more than $20bn¹. Both figures are the company's own estimates.

Caveats

AstraZeneca has not published the PK and PD data behind the AZD9750 decision, and it gave only strategic reasons for AZD8359². The early-phase trials were small when they stopped, so the cuts say little about the targets themselves. Detail on trial starts and readout timing sits in the company's clinical trials appendix, which accompanies the 30 October results¹.